For Abstracts in Congress follow the link
2023 - Counteracting Interleukin-15 to Elucidate Its Modes of Action in Physiology and Pathology. Mortier E., Maillasson M., Quéméner A. J. Interferon Cytokine Res. 43(1):2-22. doi: 10.1089/jir.2022.0198.
2022 - Selective Targeting of IL-15Rα Is Sufficient to Reduce Inflammation. Meghnem D., Maillasson M., Barbieux I., Morisseau S., Keita D., Jacques Y., Quéméner A., and Mortier E. Front. Immunol. 13:886213. doi: 10.3389/fimmu.2022.886213.
HAL: <inserm-03672135>
2021 - Rational modification, synthesis and biological evaluation of N-substituted phthalazinone derivatives designed to target interleukine-15 protein. Smadja J., Quéméner A., Maillasson M., Sicard B., Leray A., Arzel A., Lebreton J., Mortier E., Dubreuil D., and Mathé-Allainmat M. Bioorg. Med. Chem.39:116161. doi.org/10.1016/j.bmc.2021.116161.
HAL: <inserm-03214947v3>
2020 - eBook: Modulating Cytokines as Treatment for Autoimmune Diseases and Cancer. Mortier E., Ma A., Malynn B.A., and Neurath M.F. Front. Immunol. doi: 10.3389/978-2-88966-211-1.
HAL: <inserm-03079706v1>
.
2020 - Interleukin-15 and cancer. Some solved and many unsolved questions. Fiore P., Di Matteo S., Tumino N., Mariotti F., Pietra G., Ottonello S., Negrini S., Bottazzi B., Moretta L., Mortier E.* and Azzarone B.* J. ImmunoTher. Cancer. doi: 10.1136/jitc-2020-001428. (* corresponding authors)
HAL: <inserm-03013809v1>
2020 - Editorial: Modulating Cytokines as Treatment for Autoimmune Diseases and Cancer. Mortier E., Ma A., Malynn B.A., and Neurath M.F. Front. Immunol., 11:1. doi: 10.3389/fimmu.2020.608636.
HAL: <inserm-02971041v1>
2020 - IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment. Desbois M., Béal C., Charrier M., Besse B., Meurice G., Cagnard N., Jacques Y., Béchard D., Cassard L., and Chaput N. J. Immunother. Cancer. 8(1):e000632. doi: 10.1136/jitc-2020-000632.
HAL: <inserm-03498336v1>
2019 - IL-15Rα membrane anchorage in either cis or trans is required for stabilization of IL-15 and optimal signaling. Quéméner A., Morisseau S., Sousa R.P., Trillet K., Maillasson M., Leray I., Jacques Y., Dion J., Barbieux I., Frutoso M., Laurent A.D., Le Questel J.Y., and Mortier E. J. Cell. Sci. 133(5):jcs236802. doi: 10.1242/jcs.236802.
HAL: ⟨inserm-02345095⟩
2019 - NK Cell Hyporesponsiveness: More Is Not Always Better. Frutoso M., and Mortier E. Int. J. Mol. Sci. 20(18):4514. doi: 10.3390/ijms20184514. Review.
HAL: ⟨inserm-02289319⟩
2019 - Mechanistic and Structural Insights on the IL-15 System through Molecular Dynamics Simulations. Sousa R.P., Laurent A.D., Quéméner A., Mortier E., and Le Questel J.Y. Molecules. 24(18):3261. doi: 10.3390/molecules24183261.
HAL: ⟨inserm-02289307⟩
2018 - Emergence of NK Cell Hyporesponsiveness after Two IL-15 Stimulation Cycles. Frutoso M., Morisseau S., Tamzalit F., Quéméner A., Meghnem D., Leray I., Jacques Y., and Mortier E. J. Immunol. 201(2):493-506. doi: 10.4049/jimmunol.1800086.
HAL: ⟨inserm-01805185⟩
2017 - Discovery of a Small-Molecule Inhibitor of Interleukin 15: Pharmacophore-Based Virtual Screening and Hit Optimization. Quéméner A., Maillasson M., Arzel L., Sicard B.,Vomiandry R., Mortier E., Dubreuil D., Jacques Y., Lebreton J., and Mathé-Allainmat M. J. Med. Chem. 60(14):6249-6272. doi: 10.1021/acs.jmedchem.7b00485.
HAL: ⟨inserm-01550121⟩
2017 - Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc Receptor. Meghnem D., Morisseau S., Frutoso M., Trillet K., Maillasson M., Barbieux I., Khaddage S., Leray I., Hildinger M., Quéméner A., Jacques Y., and Mortier E. J. Immunol. 198(12):4563-4568. doi: 10.4049/jimmunol.1700046.
HAL: ⟨inserm-01524397⟩
2016 - [Interleukin 2 revival: a revisited model and new therapeutic applications]. Jacques Y., and Mortier E. Med. Sci. (Paris). 32(6-7):612-8. doi: 10.1051/medsci/20163206025.
HAL: ⟨inserm-01419855⟩
2016 - IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists. Desbois M., Le Vu P., Coutzac C., Marcheteau E., Béal C., Terme M., Gey A., Morisseau S., Teppaz G., Boselli L., Jacques Y., Béchard D., Tartour E., Cassard L., and Chaput N. J. Immunol. 197(1):168-78. doi: 10.4049/jimmunol.1600019.
HAL: <inserm-01823361v1>
2015 - Syndecan-1 regulates the biological activities of interleukin-34. Segaliny A.I., Brion R., Mortier E., Maillasson M., Cherel M., Jacques Y., Le Goff B., and Heymann D. Biochim. Biophys. Acta. 1853(5):1010-21. doi: 10.1016/j.bbamcr.2015.01.023.
HAL: ⟨inserm-01644783⟩
2014 - [Cut the cord, you’re ready to set off on your own!]. Mortier E., Tamzalit F., Jacques Y., Morisseau S. Med. Sci. (Paris). 30(10):836-8. doi: 10.1051/medsci/20143010006. Review. French.
HAL: ⟨inserm-02437321⟩
2014 - Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse. Vincent M., Teppaz G., Lajoie L., Solé V., Bessard A., Maillasson M., Loisel S., Béchard D., Clémenceau B., Thibault G., Garrigue-Antar L., Jacques Y., and Quéméner A. MAbs. 6(4):1026-37. doi: 10.4161/mabs.28699.
2014 - IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells. Tamzalit F., Barbieux I., Plet A., Heim J., Nedellec S., Morisseau S., Jacques Y., and Mortier E. Proc. Natl. Acad. Sci. U. S. A.111(23):8565-70. doi: 10.1073/pnas.1405514111.
HAL: ⟨inserm-02437298⟩
2014 - Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering. Romero A.I., Chaput N., Poirier-Colame V., Rusakiewicz S., Jacquelot N., Chaba K., Mortier E., Jacques Y., Caillat-Zucman S., Flament C., Caignard A., Messaoudene M., Aupérin A., Vielh P., Dessen P., Porta C., Mateus C., Ayyoub M., Valmori D., Eggermont A., Robert C., and Zitvogel L. Cancer Res. 74(1):68-80. doi: 10.1158/0008-5472.CAN-13-1186.
HAL: <inserm-02442721v1>
2013 - Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI. Vincent M., Quéméner A., and Jacques Y. Oncoimmunology.2(11):e26441. doi: 10.4161/onci.26441.
HAL: <inserm-02440743v1>
2013 - Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Vincent M., Bessard A., Cochonneau D., Teppaz G., Solé V., Maillasson M., Birklé S., Garrigue-Antar L., Quéméner A., and Jacques Y. Int. J. Cancer. 133(3):757-65. doi: 10.1002/ijc.28059.
HAL: <inserm-02440732v1>
2011 - Autonomous and extrinsic regulation of thymopoiesis in human immune system (HIS) mice. Huntington N.D., Alves N.L., Legrand N., Lim A., Strick-Marchand H., Plet A., Weijer K., Jacques Y., Spits H., and Di Santo JP. Eur. J. Immunol. 41(10):2883-93. doi: 10.1002/eji.201141586.
2011 - Despite an impaired response to IL-7, CD4+EM T cells from HIV-positive patients proliferate normally in response to IL-15 and its superagonist, RLI. Pacheco Y., Solé V., Billaud E., Allavena C., Plet A., Ferré V., Garrigue-Antar L., Raffi F., Jacques Y., and McIlroy D. AIDS. 25(14):1701-10. doi: 10.1097/QAD.0b013e328349a437.
2011 - IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo. Huntington N.D., Alves N.L., Legrand N., Lim A., Strick-Marchand H., Mention J.J., Plet A., Weijer K., Jacques Y., Becker P.D., Guzman C., Soussan P., Kremsdorf D., Spits H., and Di Santo J.P. Proc. Natl. Acad. Sci. U. S. A.108(15):6217-22. doi: 10.1073/pnas.1019167108.
2010 - Evolution of interleukin-15 for higher E. coli expression and solubility. Béhar G., Solé V., Defontaine A., Maillasson M., Quéméner A., Jacques Y., and Tellier C. Protein Eng. Des. Sel. 24(3):283-90. doi: 10.1093/protein/gzq107.
HAL: <inserm-02442555v1>
2010 - Different dynamics of IL-15R activation following IL-15 cis- or trans-presentation. Perdreau H., Mortier E., Bouchaud G., Solé V., Boublik Y., Plet A., and Jacques Y. Eur. Cytokine Netw. 21(4):297-307. doi: 10.1684/ecn.2010.0207.
HAL: ⟨inserm-02437096⟩
2010 - Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease. Bouchaud G., Mortier E., Flamant M., Barbieux I., Plet A., Galmiche J.P., Jacques Y., and Bourreille A. Gastroenterology. 138(7):2378-87. doi: 10.1053/j.gastro.2010.02.044.
HAL: ⟨inserm-02442031⟩
2009 - High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Bessard A., Solé V., Bouchaud G., Quéméner A., and Jacques Y. Mol. Cancer Ther. 8(9):2736-45. doi: 10.1158/1535-7163.MCT-09-0275.
HAL: <inserm-02440759v1>
2009 - IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. Huntington N.D., Legrand N., Alves N.L., Jaron B., Weijer K., Plet A., Corcuff E., Mortier E., Jacques Y., Spits H., and Di Santo J.P. J. Exp. Med. 206(1):25-34. doi: 10.1084/jem.20082013.
HAL: <inserm-02442774v1>
2008 - The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. Bouchaud G., Garrigue-Antar L., Solé V., Quéméner A., Boublik Y., Mortier E., Perdreau H., Jacques Y., and Plet A. J. Mol. Biol. 382(1):1-12. doi: 10.1016/j.jmb.2008.07.019.
HAL: ⟨inserm-02533457⟩
2008 - The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Badoual C., Bouchaud G., Agueznay Nel H., Mortier E., Hans S., Gey A., Fernani F., Peyrard S., Puig P.L., Bruneval P., Sastre X., Plet A., Garrigue-Antar L., Quintin-Colonna F., Fridman W.H., Brasnu D., Jacques Y., and Tartour E. Cancer Res. 68(10):3907-14. doi: 10.1158/0008-5472.CAN-07-6842.
HAL: <inserm-02442631v1>
2007 - Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Walzer T., Chiossone L., Chaix J., Calver A., Carozzo C., Garrigue-Antar L., Jacques Y., Baratin M., Tomasello E., and Vivier E. Nat. Immunol. 8(12):1337-44. doi: 10.1038/ni1523.
2006 - Docking of human interleukin-15 to its specific receptor alpha chain: correlation between molecular modeling and mutagenesis experimental data. Quéméner A., Bernard J., Mortier E., Plet A., Jacques Y., and Tran V. Proteins. 65(3):623-36. doi: 10.1002/prot.21103.
HAL: <inserm-02442432v1>
2006 - The structure of the interleukin-15 alpha receptor and its implications for ligand binding. Lorenzen I., Dingley A.J., Jacques Y., and Grötzinger J. J. Biol. Chem. 281(10):6642-7. doi: 10.1074/jbc.M513118200.
2006 - Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. Mortier E., Quéméner A., Vusio P., Lorenzen I., Boublik Y., Grötzinger J., Plet A., and Jacques Y. J. Biol. Chem. 281(3):1612-9. doi: 10.1074/jbc.M508624200.
HAL: <inserm-02442379v1>
2005 - Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. Rabu C., Quéméner A., Jacques Y., Echasserieau K., Vusio P., and Lang F. J. Biol. Chem. 280(50):41472-81. doi: 10.1074/jbc.M506881200.
HAL: <inserm-02442588v1>
2005 - Expression of a bioactive recombinant human interleukin-11 in chicken HD11 cell line. Léon A., Wang X.M., Champion-Arnaud P., Sobczyk A., Pain B., Content J., Jacques Y., and Valarché I. Cytokine. 30(6):382-90. doi: 10.1016/j.cyto.2005.02.003.
2004 - Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. Mortier E., Bernard J., Plet A., and Jacques Y. J. Immunol. 173(3):1681-8. doi: 10.4049/jimmunol.173.3.1681.
HAL: ⟨inserm-02437358⟩
2004 - Identification of an interleukin-15alpha receptor-binding site on human interleukin-15. Bernard J., Harb C., Mortier E., Quéméner A., Meloen R.H., Vermot-Desroches C., Wijdeness J., van Dijken P., Grötzinger J., Slootstra J.W., Plet A., and Jacques Y. J. Biol. Chem. 279(23):24313-22. doi: 10.1074/jbc.M312458200.
HAL: <inserm-02442410v1>
